Evidence map›Paper›PMID 36968964›Full record

ArticleOpen forum infectious diseases2023

Trends in

Salini Mohanty, Kristen Feemster, Kalvin C Yu, Janet A Watts, Vikas Gupta

Open access · goldFull text read
In one paragraph

Article in Open forum infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Antimicrobial resistance ofFrontiers in public health · 2024
    Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Global Antimicrobial Non-Susceptibility Patterns ofInfection and drug resistance · 2026
    Review
  7. Article
  8. Clinical microbiology reviews · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Genomic surveillance of invasiveMicrobial genomics · 2025
    Article
  14. Article
  15. Article
  16. The Evolution of the Antimicrobial Resistance ofAntibiotics (Basel, Switzerland) · 2025
    Article
  17. Review
  18. Article
  19. Frontiers in public health · 2025
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Salini MohantyCenter for Observational and Real World Evidence (CORE), Merck & Co, Inc, Rahway, New Jersey, USA.
Kristen FeemsterCenter for Observational and Real World Evidence (CORE), Merck & Co, Inc, Rahway, New Jersey, USA.
Kalvin C YuBecton, Dickinson & Company, Franklin Lakes, New Jersey, USA.
Janet A WattsBecton, Dickinson & Company, Franklin Lakes, New Jersey, USA.
Vikas GuptaBecton, Dickinson & Company, Franklin Lakes, New Jersey, USA.ORCID https://orcid.org/0000-0001-5291-5446
Becton Dickinson (United States) · USMerck & Co., Inc., Rahway, NJ, USA (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Antimicrobial resistance (AMR) poses a significant challenge for treating pneumococcal disease. This study assessed AMR trends in Methods: We evaluated antibiotic resistance, defined as facility antimicrobial susceptibility reports of intermediate/resistant, in 30-day nonduplicate Results: Of 7605 Conclusions: Among US children over the last decade,

Indexed as

antibiotic resistancechildreninvasive pneumococcal vaccinespneumococcal diseaseStreptococcus pneumoniae

Identifiers

PMID36968964
PMCPMC10034583
OpenAlexW4323350138

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read76
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.